GleamWall
中文EN

BIXT BIOXYTRAN, INC

Pharmaceutical Preparations · OTC · SEC CIK 1445815 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-57.2%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,453.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,582.1%
Debt / equity—
Current ratio0.03x
Interest coverage-25.47x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-1,092.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$255,479$225,479$2,000$0$102,500$349,500$34,337$51,000
SG&A expense$189,121$213,974$235,799$159,131$94,529$143,770$399,452$158,071
Operating income-$654,600-$1.93M-$607,285-$496,005-$224,077-$515,142-$483,688-$346,204
Interest expense$36,126$35,729$36,523$36,522$30,112$31,157$20,290$17,845
Pretax income-$619,929-$2.07M-$522,155-$282,726$35,439-$1.35M-$512,268-$392,374
Net income-$619,929-$2.07M-$522,155-$282,726$35,439-$1.35M-$512,268-$392,374
EPS (basic)-0.01-0.02—0.000.00-0.02—0.00
EPS (diluted)-0.01-0.02—0.000.00-0.02—0.00
Weighted avg. shares (diluted)114.36M112.28M—88.99M88.84M88.84M—126.39M
Banking
Deposits—$188,464$111,547—————
Balance sheet
Cash & equivalents$177,384$463,047$509,914$14,499$3,144$4,348$5,154$34,672
Current assets$177,384$463,047$513,465$14,499$3,144$4,348$5,154$34,672
Intangibles$156,009$152,206$145,087$141,795$144,357$131,704$133,540$124,336
Total assets$333,393$615,253$658,552$156,294$147,501$136,052$138,694$159,008
Current liabilities$5.27M$5.01M$3.25M$3.06M$2.78M$2.84M$1.93M$1.24M
Short-term debt————$48,070$48,000$48,000—
Total liabilities$5.27M$5.01M$3.25M$3.06M$2.78M$2.84M$1.93M$1.24M
Shareholders' equity-$4.94M-$4.39M-$2.59M-$2.90M-$2.64M-$2.71M-$1.79M-$1.08M
Shares outstanding114.70M113.36M108.15M88.99M88.99M88.88M86.78M82.24M
Cash flow statement
Operating cash flow-$349,773-$238,610-$236,971-$41,474-$80,687-$167,323-$127,937-$73,547
Investing cash flow-$9,383-$9,227-$6,240-$1,674-$15,162-$15-$12,071-$10,821
Financing cash flow$73,493$200,970$738,626$54,503$94,645$166,532$110,490$105,518
Stock-based compensation$7,815$1.29M$84,574$43,741$40,461$26,998$446,508$8,416

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.